TRINITY BIOTECH PLC — Regulatory Filings 2023

Dec 19, 2023

6-K 1 zk2330672.htm 6-K Licensed to: Z-K Global Document created using Broadridge PROfile 23.9.1.5178 Copyright 1995 - 2023 Broadridge

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2023

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow

Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ____

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279,333-195232 and 333-253070) and Registration Statements on Form F-3 (File Nos. 333-239701 and 333-264992).

EXPLANATORY NOTE

On December 18, 2023, Trinity Biotech plc issued a press release announcing the promotion of John Gillard, its Chief Financial Officer, to President and Chief Executive Officer. Additionally, Des Fitzgerald, who has served as Director of Corporate Development of Trinity Biotech since October 2022, has been promoted to Interim Chief Financial Officer, succeeding Mr. Gillard in that role. A copy of the press release is filed herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit	Description
99.1	Trinity Biotech Plc Announces Management Changes. John Gillard Named Chief Executive
Officer. Des Fitzgerald Named Interim Chief Financial Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TRINITY BIOTECH PLC
	Trinity Biotech plc
	(Registrant)
By:	/s/ Des Fitzgerald
	Des Fitzgerald
	Interim Chief Financial Officer

Date: December 19, 2023